The treatment called osimertinib targets non-small cell cancer that has a particular type of mutation.
An already-available drug shows evidence of helping to increase the survival rate in patients with EGRF mutations of non-small cell lung cancer. — AFP
Lung cancer is the form of the disease that causes the most deaths, with approximately 1.8 million fatalities every year worldwide. The clinical trial included some 680 participants at an early stage of the disease , in more than 20 countries. After five years, 88% of patients who took the treatment were still alive, compared to 78% of patients who took the placebo.
"We started entering the personalised therapy era for early stage patients," said the medical oncologist, who did not take part in the trials, and noted that"we should firmly close the door on one-size-fits-all treatment for people with non-small cell lung cancer."